// App-Quantinova.ai

[OP0168] : SECUKINUMAB SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM MEASURE 2, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING

Researchers

Presenter

  • J. Sieper

Principal Investigators

  • J. Braun

  • X. Baraliakos

  • H. Richards

  • D.L. Baeten

  • M. Dougados

  • P. Emery

  • A. Deodhar

  • J. C.C. Wei

  • B. Porter

  • M. Andersson

  • S. Mpofu

Medical Centers

  • University Paris Descartes & Hopital Necker, Paris, France

  • University of Leeds, Leeds, United Kingdom

  • Oregon Health and Science University, Portland, Oregon, United States

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • Academic Medical Center, Amsterdam, Netherlands

Locations

  • Netherlands

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Inflammatory Arthritis

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved